Cancer Health Forums

Liver Cancer Forums => Living with Liver Cancer => Topic started by: Cancer Health Editors on December 04, 2019, 01:08:18 pm

Title: Opdivo Plus Yervoy Shows Promise for Advanced Liver Cancer
Post by: Cancer Health Editors on December 04, 2019, 01:08:18 pm
Combining two different types of checkpoint inhibitor immunotherapy led to improved outcomes in people with advanced liver cancer, according to study results presented this week at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD).

People treated with the most effective regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) had an overall response rate of 32% and a median survival of nearly two years—better than the outcomes seen with Opdivo alone. The dual treatment was generally safe and side effects were described as manageable.

Over years or decades, chronic hepatitis B or C, heavy alcohol use, fatty liver disease and other causes can lead to the development of liver cirrhosis and hepatocellular carcinoma (HCC), the most common type of liver cancer. HCC is often detected late and is difficult to treat, as it generally does not respond well to traditional chemotherapy. Opdivo and a similar immunotherapy, Keytruda (pembrolizumab), as well as several targeted therapies, have been approved for HCC treatment in recent years.

Read more...
https://www.cancerhealth.com/article/opdivo-plus-yervoy-shows-promise-advanced-liver-cancer